Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 7/20 | 0.76 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.76 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953602 | 1.00 | SLC1A3 (0.76) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL418322 | 1.00 | SLC1A3 (0.76) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| Water SCHEMBL30419716 | 0.98 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL28285770 | 0.91 | SLC1A2 (0.65) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL21873930 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2596995 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2597203 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2004120 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2004125 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2819524 | 0.87 | SLC1A2 (1.00) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116271245-A | Bionic tendon sheath membrane with medicine slow-release function and preparation method thereof | 河北医科大学第三医院 | 2023-06-23 | — | — | CN | claimed |
| US-8778069-B2 | Phase change inks containing oligomeric rosin esters | XEROX CORPORATION (US) | 2014-07-15 | — | — | US | claimed |
| US-20140137767-A1 | Phase Change Inks Containing Oligomeric Rosin Esters | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | claimed |
| WO-2009084024-A2 | A PROCESS FOR THE PREPARATION OF R-SIT AGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| EP-3807243-B1 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL | PHARMATHEN SA (GR) | 2024-05-22 | — | — | EP | disclosed |
| CN-112424177-B | One-pot organic pseudo-catalytic C-H activation method for preparing vortioxetine and vortioxetine intermediate | VIO制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-01-25 | — | — | US | disclosed |
| US-11851503-B2 | Antiplasmodial compounds | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-116271245-A | Bionic tendon sheath membrane with medicine slow-release function and preparation method thereof | 河北医科大学第三医院 | 2023-06-23 | — | — | CN | disclosed |
| US-20220144894-A1 | ANTIPLASMODIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11230569-B2 | Antiplasmodial compounds | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11198671-B2 | One-pot organo-pseudocatalytic C—H activation approach for the preparation of vortioxetine and vortioxetine intermediate | VIO AG PHARMACEUTICALS S.A. (GR) | 2021-12-14 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6320069-B1 | REACTING RACEMIC ALCOHOL WITH OPTICALLY ACTIVE AMINO ACID TO PRODUCE AMINO ACID ESTER, PERFORMING DIASTEREOMER RESOLUTION THEREON BY PROCESS SELECTED FROM CRYSTALLIZATION SEPARATION, COLUMN SEPARATION AND SIMULATED MOVING BED SEPARATION | TORAY INDUSTRIES, INC. (JP) | 2001-11-20 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0924180-A1 | PROCESSES FOR THE PREPARATION OF OPTICALLY ACTIVE KETONES | TORAY INDUSTRIES, INC. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-4652672-A | BETA BLOCKERS | LINDNER WOLFGANG F (AT) | 1987-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | DPP4, NT5C, DPP7 | SLC1A3 2362/4885SLC1A2 2776/4885SLC1A1 2051/4885 |
| US-11230569-B2 | Antiplasmodial compounds | MGST3, G6PD, GPX4 | SLC1A3 4087/4885SLC1A2 4437/4885SLC1A1 4034/4885 |
| US-11198671-B2 | One-pot organo-pseudocatalytic C—H activation approach for the preparation of vortioxetine and vortioxetine intermediate | DBH, HTR5A, SLC6A4 | SLC1A3 2371/4885SLC1A2 1493/4885SLC1A1 2352/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | SLC1A3 4116/4885SLC1A2 3004/4885SLC1A1 3025/4885 |
| US-20220144894-A1 | ANTIPLASMODIAL COMPOUNDS | MGST3, G6PD, GPX4 | SLC1A3 4087/4885SLC1A2 4437/4885SLC1A1 4034/4885 |
| US-11851503-B2 | Antiplasmodial compounds | MGST3, G6PD, GPX4 | SLC1A3 4087/4885SLC1A2 4437/4885SLC1A1 4034/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | SLC1A3 4116/4885SLC1A2 3004/4885SLC1A1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.